Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
Portfolio Pulse from Vandana Singh
Biogen's Alzheimer's drug, Leqembi, has been approved by the UK's Medicines and Healthcare products Regulatory Agency. However, the National Institute for Health and Care Excellence (NICE) does not recommend it for NHS reimbursement due to cost-effectiveness concerns. Despite showing a small benefit in slowing disease progression, the drug's high costs and limited long-term evidence are barriers.
August 22, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen's Alzheimer's drug Leqembi received UK approval but faces reimbursement challenges due to cost concerns. This could limit its market potential despite being the first treatment targeting early Alzheimer's disease.
The approval of Leqembi in the UK is a positive development for Biogen, but the lack of recommendation for NHS reimbursement due to cost concerns is a significant setback. This limits the drug's market potential in the UK, impacting Biogen's revenue prospects. The stock's recent decline reflects investor concerns over these reimbursement challenges.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90